Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Pass Above 200-Day Moving Average – What’s Next?

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $49.31 and traded as high as $50.78. Supernus Pharmaceuticals shares last traded at $50.06, with a volume of 438,153 shares.

Wall Street Analyst Weigh In

A number of research analysts have commented on SUPN shares. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 8th. Stifel Nicolaus lifted their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, December 19th. Finally, Zacks Research cut Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Trading Up 1.4%

The business has a fifty day moving average of $50.99 and a 200-day moving average of $49.31. The company has a market cap of $2.88 billion, a PE ratio of -73.62, a P/E/G ratio of 1.53 and a beta of 0.70.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,250 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total value of $359,600.00. Following the completion of the transaction, the vice president directly owned 17,044 shares in the company, valued at approximately $845,382.40. This represents a 29.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Georges Gemayel sold 8,787 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the sale, the director directly owned 27,277 shares of the company’s stock, valued at approximately $1,445,681. This represents a 24.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 120,881 shares of company stock worth $6,139,356. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its stake in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares during the period. Rockefeller Capital Management L.P. raised its holdings in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares in the last quarter. Torren Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at $49,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals during the 3rd quarter valued at about $50,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth about $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.